Ret Proto-Oncogene anticorps (AA 1012-1042)
Aperçu rapide pour Ret Proto-Oncogene anticorps (AA 1012-1042) (ABIN3032460)
Antigène
Voir toutes Ret Proto-Oncogene (RET) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 1012-1042
-
Fonction
- RET Antibody
-
Purification
- Purified
-
Immunogène
- A portion of amino acids 1012-1042 from the human protein was used as the immunogen for this RET antibody.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- Titration of the RET antibody may be required due to differences in protocols and secondary/substrate sensitivity.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- In 1X PBS, pH 7.4, with 0.09 % sodium azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Aliquot the RET antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- Ret Proto-Oncogene (RET)
-
Autre désignation
- RET
-
Sujet
- RET, a member of the cadherin superfamily, is one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This protein plays a crucial role in neural crest development, and the gene can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations i are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma.
-
UniProt
- P07949
-
Pathways
- Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Antigène
-